Integration of large-scale chromatography with nanofiltration for an ovine polyclonal product

Pharmaceutical Technology

Volumn 33, Issue 1, 2009, Pages 62-70

  Denton, Aline ^a   Jones, Carl ^a   Tarrach, Klaus ^b  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

^b SARTORIUS STEDIM BIOTECH GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CANDIDATES; POLYCLONAL; POLYCLONAL ANTIBODY; PROCESS DEVELOPMENT;

CHROMATOGRAPHY; INTEGRATION; PURIFICATION;

NANOFILTRATION;

CHROMATOGRAPHY; GOOD LABORATORY PRACTICE; NANOFILTRATION; NONHUMAN; PURIFICATION; REVIEW; SHEEP; VIRUS SPIKE;

EID: 77951860805     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. K. DiBlasi et al., "Disposable Biopharmaceutical Processes, Myth or Reality?, " BioPharm Int., Nov. 2006 supplement, 6-16.
2. R. Francis, "Efficient Process Development Strategies Can Translate into Robust Large-Scale Manufacturing, " presented at the IBC Conference, San Francisco, Nov. 2006.
3. C. Jones and A. Denton, "Integration of Large Scale Chromatography with Nanofiltration for an Ovine Polyclonal Product, " presented at the European Downstream Technology Forum, Sartorius College, Goettingen, Germany, May 2007.
4. K. Tarrach et al., "The Effect of Flux Decay on a 20-nm Nanofilter for Virus Retention, " BioPharm Int., April, 58-63, 2007.
5. K. Tarrach, "Integrative Strategies for Viral Clearance, " presented at the 4th Annual Biological Production Forum, Edinburgh, Apr. 2005.
6. K. Brorson, "Virus Filter Validation and Performance, " presented at the Recovery of Biological Products XII conference, Phoenix, AZ, Apr. 2006.
7. EMEA/CPMP, Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (London, Feb. 1996), available at http://www.emea.europa.eu/ pdfs/human/bwp/026895en.pdf. accessed on Dec. 19, 2008.
8. ICH and FDA, Q5A Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (Geneva, Switzerland and Rockville, MD, Sept. 1998).
9. M. Cabatingan, "Impact of Virus Stock Quality on Virus Filter Validation, A Case Study, " BioProcess Int., Nov. 2005 supplement, 39-43.
10. T. Ireland et al., "Vird Filtration of Plasma-Derived Human IgG: A Case Study Using Viresolve NFP, " BioPharm Int. 17 (11), 38-44 (2004).
11. A. Higuchi et al., "Effect of Aggregated Protein Sizes on the Flux of Protein Solution Through Microporous Membranes." J. Membrane Sci. 236 (1-2), 137-144 (2004).
12. K. Tarrach, "Virus Filter Positioning in the Purification Process of Cell Culture Intermediates and Flow Decay Aspects Associated with Small Non-Enveloped Virus Retention, " presented at the BioProcess International European Conference and Exhibition, Paris, Apr. 2007.